Barclays raised the firm’s price target on Amneal Pharmaceuticals to $8 from $6 and keeps an Overweight rating on the shares. The analyst sees the generics and biosimilars outlook as the “healthiest in years,” with easing generic deflation and rising loss of exclusivity opportunities. The firm upgraded the specialty pharmaceuticals industry to Positive.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMRX:
- Knight Therapeutics, Amneal Pharmaceuticals enter license agreement
- Amneal Pharmaceuticals to transfer its stock exchange listing to Nasdaq
- Amneal Pharmaceuticals announces Ongentys licensing agreement
Questions or Comments about the article? Write to editor@tipranks.com